{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:22:06Z","timestamp":1793816526014,"version":"4.6.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Anhui Province Scientific Research Staffing Plan Project","award":["AH050668"],"award-info":[{"award-number":["AH050668"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05998-8","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T10:05:08Z","timestamp":1735034708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2686-6918","authenticated-orcid":false,"given":"Weiwei","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8211-6554","authenticated-orcid":false,"given":"Song","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"issue":"2","key":"5998_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"3","key":"5998_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA A Cancer J Clin"},{"key":"5998_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103841","volume":"181","author":"MJ L\u00f3pez","year":"2023","unstructured":"L\u00f3pez MJ, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023;181: 103841.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"5998_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/microorganisms12010222","volume":"12","author":"A Ali","year":"2024","unstructured":"Ali A, AlHussaini KI. Helicobacter pylori: a contemporary perspective on pathogenesis, diagnosis and treatment strategies. Microorganisms. 2024;12(1):222.","journal-title":"Microorganisms"},{"issue":"1","key":"5998_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12879-017-2412-y","volume":"17","author":"P Cao","year":"2017","unstructured":"Cao P, et al. Fluorescence in situ hybridization is superior for monitoring Epstein Barr viral load in infectious mononucleosis patients. BMC Infect Dis. 2017;17(1):323.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"5998_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cyt.12053","volume":"25","author":"PH Braz-Silva","year":"2014","unstructured":"Braz-Silva PH, et al. Oral hairy leukoplakia diagnosis by Epstein-Barr virus in situ hybridization in liquid-based cytology. Cytopathology. 2014;25(1):21\u20136.","journal-title":"Cytopathology"},{"issue":"4","key":"5998_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.21873\/invivo.11126","volume":"31","author":"SJ Na","year":"2017","unstructured":"Na SJ, et al. Correlation between infection status of Epstein-Barr Virus and (18)F-fluorodeoxyglucose uptake in patients with advanced gastric cancer. In Vivo. 2017;31(4):749\u201353.","journal-title":"In Vivo"},{"issue":"4","key":"5998_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/a-2041-2986","volume":"235","author":"T Shi","year":"2023","unstructured":"Shi T, et al. Identification of ADA as a biomarker for atypical Epstein Barr Virus infection in children. Klin Padiatr. 2023;235(4):221\u20137.","journal-title":"Klin Padiatr"},{"issue":"17","key":"5998_CR9","doi-asserted-by":"publisher","first-page":"28796","DOI":"10.18632\/oncotarget.15675","volume":"8","author":"K Shoda","year":"2017","unstructured":"Shoda K, et al. Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer. Oncotarget. 2017;8(17):28796\u2013804.","journal-title":"Oncotarget"},{"issue":"4","key":"5998_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3748\/wjg.v21.i4.1305","volume":"21","author":"M Ferwana","year":"2015","unstructured":"Ferwana M, et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol. 2015;21(4):1305\u201314.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5998_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000538349","volume":"33","author":"L Costa","year":"2024","unstructured":"Costa L, et al. Diagnostic methods for Helicobacter pylori. Med Princ Pract. 2024;33(3):173\u201384.","journal-title":"Med Princ Pract"},{"issue":"45","key":"5998_CR12","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.3748\/wjg.v19.i45.8188","volume":"19","author":"T Shimoyama","year":"2013","unstructured":"Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19(45):8188\u201391.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"5998_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5334\/aogh.2570","volume":"85","author":"MA Abd Rahim","year":"2019","unstructured":"Abd Rahim MA, et al. (13)C-urea breath test accuracy for Helicobacter pylori infection in the Asian population: a meta-analysis. Ann Glob Health. 2019;85(1):110.","journal-title":"Ann Glob Health"},{"key":"5998_CR14","doi-asserted-by":"publisher","first-page":"4819423","DOI":"10.1155\/2016\/4819423","volume":"2016","author":"M Miftahussurur","year":"2016","unstructured":"Miftahussurur M, Yamaoka Y. Diagnostic methods of Helicobacter pylori infection for epidemiological studies: critical importance of indirect test validation. Biomed Res Int. 2016;2016:4819423.","journal-title":"Biomed Res Int"},{"issue":"1","key":"5998_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12903-018-0541-3","volume":"18","author":"G Dahlen","year":"2018","unstructured":"Dahlen G, et al. Rapid urease test (RUT) for evaluation of urease activity in oral bacteria in vitro and in supragingival dental plaque ex vivo. BMC Oral Health. 2018;18(1):89.","journal-title":"BMC Oral Health"},{"key":"5998_CR16","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2017.4","volume":"19","author":"M Miftahussurur","year":"2017","unstructured":"Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017;19: e4.","journal-title":"Expert Rev Mol Med"},{"key":"5998_CR17","unstructured":"Shreffler J, Huecker MR. Diagnostic testing accuracy: sensitivity, specificity, predictive values and likelihood ratios, in StatPearls. 2024: Treasure Island (FL) ineligible companies. Disclosure: Martin Huecker declares no relevant financial relationships with ineligible companies."},{"issue":"2","key":"5998_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCG.0000000000001719","volume":"57","author":"P Katelaris","year":"2023","unstructured":"Katelaris P, et al. Helicobacter pylori world gastroenterology organization global guideline. J Clin Gastroenterol. 2023;57(2):111\u201326.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"5998_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bpg.2006.11.002","volume":"21","author":"C Ricci","year":"2007","unstructured":"Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Pract Res Clin Gastroenterol. 2007;21(2):299\u2013313.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"36","key":"5998_CR20","doi-asserted-by":"publisher","first-page":"12847","DOI":"10.3748\/wjg.v20.i36.12847","volume":"20","author":"SK Patel","year":"2014","unstructured":"Patel SK, et al. Diagnosis of Helicobacter pylori: what should be the gold standard? World J Gastroenterol. 2014;20(36):12847\u201359.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5998_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/ije\/dyw078","volume":"45","author":"H Cai","year":"2016","unstructured":"Cai H, et al. Helicobacter pylori blood biomarker for gastric cancer risk in East Asia. Int J Epidemiol. 2016;45(3):774\u201381.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"5998_CR22","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/jjco\/hyt166","volume":"43","author":"T Matsuda","year":"2013","unstructured":"Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 2013;43(11):1157\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"5998_CR23","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2023.08.028","volume":"165","author":"K Sugano","year":"2023","unstructured":"Sugano K, Moss SF, Kuipers EJ. Gastric intestinal metaplasia: real culprit or innocent bystander as a precancerous condition for gastric cancer? Gastroenterology. 2023;165(6):1352-1366.e1.","journal-title":"Gastroenterology"},{"issue":"5","key":"5998_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/annonc\/mdw040","volume":"27","author":"NY Chia","year":"2016","unstructured":"Chia NY, Tan P. Molecular classification of gastric cancer. Ann Oncol. 2016;27(5):763\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"5998_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/17474124.2021.1845140","volume":"15","author":"K Yang","year":"2021","unstructured":"Yang K, et al. A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors. Expert Rev Gastroenterol Hepatol. 2021;15(3):255\u201373.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"12","key":"5998_CR26","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1136\/gutjnl-2021-325948","volume":"71","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Nationwide gastric cancer prevention in China, 2021\u20132035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut. 2022;71(12):2391\u2013400.","journal-title":"Gut"},{"issue":"17","key":"5998_CR27","doi-asserted-by":"publisher","first-page":"21451","DOI":"10.18632\/aging.203484","volume":"13","author":"F Duan","year":"2021","unstructured":"Duan F, et al. Identification and epidemiological evaluation of gastric cancer risk factors: based on a field synopsis and meta-analysis in Chinese population. Aging (Albany NY). 2021;13(17):21451\u201369.","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"5998_CR28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(20)30460-5","volume":"21","author":"G Jin","year":"2020","unstructured":"Jin G, et al. Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study. Lancet Oncol. 2020;21(10):1378\u201386.","journal-title":"Lancet Oncol"},{"issue":"5","key":"5998_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00705-024-06033-3","volume":"169","author":"LL Li","year":"2024","unstructured":"Li LL, et al. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer. Arch Virol. 2024;169(5):114.","journal-title":"Arch Virol"},{"issue":"1","key":"5998_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00432-022-04408-0","volume":"149","author":"C R\u00f6cken","year":"2023","unstructured":"R\u00f6cken C. Predictive biomarkers in gastric cancer. J Cancer Res Clin Oncol. 2023;149(1):467\u201381.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"5998_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","volume":"75","author":"M Cargnello","year":"2011","unstructured":"Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50\u201383.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"2","key":"5998_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/jipb.13215","volume":"64","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zhang S. Mitogen-activated protein kinase cascades in plant signaling. J Integr Plant Biol. 2022;64(2):301\u201341.","journal-title":"J Integr Plant Biol"},{"issue":"4","key":"5998_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","volume":"37","author":"M Drosten","year":"2020","unstructured":"Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543\u201350.","journal-title":"Cancer Cell"},{"issue":"9","key":"5998_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41417-023-00622-1","volume":"30","author":"T Phan","year":"2023","unstructured":"Phan T, et al. P38 kinase in gastrointestinal cancers. Cancer Gene Ther. 2023;30(9):1181\u20139.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"5998_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202215705","volume":"14","author":"T Seidlitz","year":"2022","unstructured":"Seidlitz T, et al. Sensitivity towards HDAC inhibition is associated with RTK\/MAPK pathway activation in gastric cancer. EMBO Mol Med. 2022;14(10): e15705.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"5998_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41401-023-01165-9","volume":"45","author":"J-X Xiong","year":"2024","unstructured":"Xiong J-X, et al. Targeting PRSS23 with tipranavir induces gastric cancer stem cell apoptosis and inhibits growth of gastric cancer via the MKK3\/p38 MAPK-IL24 pathway. Acta Pharmacol Sin. 2024;45(2):405\u201321.","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"5998_CR37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/CM9.0000000000000742","volume":"133","author":"Z-Y Yu","year":"2020","unstructured":"Yu Z-Y, et al. Effect of KIF22 on promoting proliferation and migration of gastric cancer cells via MAPK-ERK pathways. Chin Med J. 2020;133(8):919\u201328.","journal-title":"Chin Med J"},{"issue":"7","key":"5998_CR38","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","volume":"24","author":"GS Wong","year":"2018","unstructured":"Wong GS, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018;24(7):968\u201377.","journal-title":"Nat Med"},{"issue":"1","key":"5998_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12943-021-01451-2","volume":"20","author":"B Chen","year":"2021","unstructured":"Chen B, et al. STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker. Mol Cancer. 2021;20(1):147.","journal-title":"Mol Cancer"},{"issue":"1","key":"5998_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.gastro.2023.09.040","volume":"166","author":"H Kim","year":"2024","unstructured":"Kim H, et al. Targeting stem cells and dysplastic features with dual MEK\/ERK and STAT3 suppression in gastric carcinogenesis. Gastroenterology. 2024;166(1):117\u201331.","journal-title":"Gastroenterology"},{"issue":"7","key":"5998_CR41","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41401-020-00540-0","volume":"42","author":"X Liu","year":"2021","unstructured":"Liu X, et al. MicroRNAs are involved in the development and progression of gastric cancer. Acta Pharmacol Sin. 2021;42(7):1018\u201326.","journal-title":"Acta Pharmacol Sin"},{"key":"5998_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s11658-019-0178-5","volume":"24","author":"F Jiang","year":"2019","unstructured":"Jiang F, Shen X. Current prevalence status of gastric cancer and recent studies on the roles of circular RNAs and methods used to investigate circular RNAs. Cell Mol Biol Lett. 2019;24:53.","journal-title":"Cell Mol Biol Lett"},{"issue":"5","key":"5998_CR43","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3390\/ijms21051782","volume":"21","author":"AC Anauate","year":"2020","unstructured":"Anauate AC, et al. The complex network between MYC oncogene and microRNAs in gastric cancer: an overview. Int J Mol Sci. 2020;21(5):1782.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5998_CR44","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/iub.2259","volume":"72","author":"A Ahadi","year":"2020","unstructured":"Ahadi A. Dysregulation of miRNAs as a signature for diagnosis and prognosis of gastric cancer and their involvement in the mechanism underlying gastric carcinogenesis and progression. IUBMB Life. 2020;72(5):884\u201398.","journal-title":"IUBMB Life"},{"issue":"4","key":"5998_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3892\/ijo.2021.5187","volume":"58","author":"J Ouyang","year":"2021","unstructured":"Ouyang J, et al. Clinical crosstalk between microRNAs and gastric cancer (Review). Int J Oncol. 2021;58(4):7.","journal-title":"Int J Oncol"},{"key":"5998_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144937","volume":"757","author":"S Ghafouri-Fard","year":"2020","unstructured":"Ghafouri-Fard S, et al. MicroRNAs in gastric cancer: biomarkers and therapeutic targets. Gene. 2020;757: 144937.","journal-title":"Gene"},{"issue":"5","key":"5998_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338\u201349.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5998_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1053\/j.gastro.2015.09.004","volume":"150","author":"M Amieva","year":"2016","unstructured":"Amieva M, Peek RM. Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology. 2016;150(1):64\u201378.","journal-title":"Gastroenterology"},{"issue":"1","key":"5998_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","volume":"9","author":"P Malfertheiner","year":"2023","unstructured":"Malfertheiner P, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"5998_CR50","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","volume":"166","author":"YC Chen","year":"2024","unstructured":"Chen YC, et al. Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology. 2024;166(4):605\u201319.","journal-title":"Gastroenterology"},{"issue":"5","key":"5998_CR51","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.gastro.2023.01.018","volume":"164","author":"RJ Huang","year":"2023","unstructured":"Huang RJ, et al. Controlling gastric cancer in a world of heterogeneous risk. Gastroenterology. 2023;164(5):736\u201351.","journal-title":"Gastroenterology"},{"issue":"12","key":"5998_CR52","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","volume":"69","author":"J-M Liou","year":"2020","unstructured":"Liou J-M, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093\u2013112.","journal-title":"Gut"},{"issue":"13","key":"5998_CR53","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa2211807","volume":"388","author":"Y Usui","year":"2023","unstructured":"Usui Y, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med. 2023;388(13):1181\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"5998_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41423-019-0339-5","volume":"17","author":"A Takahashi-Kanemitsu","year":"2020","unstructured":"Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17(1):50\u201363.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"5998_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/toxins10040163","volume":"10","author":"JY Park","year":"2018","unstructured":"Park JY, et al. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cancer. Toxins. 2018;10(4):163.","journal-title":"Toxins"},{"issue":"8","key":"5998_CR56","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.chom.2023.06.016","volume":"31","author":"I Sharafutdinov","year":"2023","unstructured":"Sharafutdinov I, et al. A single-nucleotide polymorphism in Helicobacter pylori promotes gastric cancer development. Cell Host Microbe. 2023;31(8):1345\u201358.","journal-title":"Cell Host Microbe"},{"issue":"6","key":"5998_CR57","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1053\/j.gastro.2022.01.046","volume":"162","author":"L Cao","year":"2022","unstructured":"Cao L, et al. Helicobacter pylori-induced RASAL2 through activation of\u00a0nuclear factor-\u03baB promotes gastric tumorigenesis via \u03b2-catenin signaling axis. Gastroenterology. 2022;162(6):1716\u201331.","journal-title":"Gastroenterology"},{"issue":"8","key":"5998_CR58","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1128\/IAI.68.8.4378-4383.2000","volume":"68","author":"H Kuwahara","year":"2000","unstructured":"Kuwahara H, et al. Helicobacter pylori urease suppresses bactericidal activity of peroxynitrite via carbon dioxide production. Infect Immun. 2000;68(8):4378\u201383.","journal-title":"Infect Immun"},{"issue":"8","key":"5998_CR59","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.tim.2020.02.004","volume":"28","author":"TL Cover","year":"2020","unstructured":"Cover TL, Lacy DB, Ohi MD. The Helicobacter pylori Cag type IV secretion system. Trends Microbiol. 2020;28(8):682\u201395.","journal-title":"Trends Microbiol"},{"key":"5998_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215764","volume":"542","author":"J He","year":"2022","unstructured":"He J, et al. Helicobacter pylori infection induces stem cell-like properties in Correa cascade of gastric cancer. Cancer Lett. 2022;542: 215764.","journal-title":"Cancer Lett"},{"issue":"7 Pt 2","key":"5998_CR61","first-page":"e67","volume":"23","author":"SZ Ding","year":"2008","unstructured":"Ding SZ, Smith MF Jr, Goldberg JB. Helicobacter pylori and mitogen-activated protein kinases regulate the cell cycle, proliferation and apoptosis in gastric epithelial cells. J Gastroenterol Hepatol. 2008;23(7 Pt 2):e67-78.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"5998_CR62","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.chom.2009.03.004","volume":"5","author":"M Selbach","year":"2009","unstructured":"Selbach M, et al. Host cell interactome of tyrosine-phosphorylated bacterial proteins. Cell Host Microbe. 2009;5(4):397\u2013403.","journal-title":"Cell Host Microbe"},{"issue":"4","key":"5998_CR63","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1097-2765(02)00681-0","volume":"10","author":"H Mimuro","year":"2002","unstructured":"Mimuro H, et al. Grb2 is a key mediator of helicobacter pylori CagA protein activities. Mol Cell. 2002;10(4):745\u201355.","journal-title":"Mol Cell"},{"issue":"8","key":"5998_CR64","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3390\/ijms21082893","volume":"21","author":"L Magnelli","year":"2020","unstructured":"Magnelli L, et al. MAP kinases pathways in gastric cancer. Int J Mol Sci. 2020;21(8):2893.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5998_CR65","first-page":"5733","volume":"18","author":"L Liu","year":"2018","unstructured":"Liu L, et al. Helicobacter pylori infection enhances heparanase leading to cell proliferation via mitogen-activated protein kinase signalling in human gastric cancer cells. Mol Med Rep. 2018;18(6):5733\u201341.","journal-title":"Mol Med Rep"},{"key":"5998_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106440","volume":"184","author":"Q Liu","year":"2022","unstructured":"Liu Q, et al. Berberine for gastric cancer prevention and treatment: multi-step actions on the Correa\u2019s cascade underlie its therapeutic effects. Pharmacol Res. 2022;184: 106440.","journal-title":"Pharmacol Res"},{"issue":"1","key":"5998_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15384047.2022.2038002","volume":"23","author":"T Yoshida","year":"2022","unstructured":"Yoshida T, et al. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. Cancer Biol Ther. 2022;23(1):191\u2013200.","journal-title":"Cancer Biol Ther"},{"issue":"20","key":"5998_CR68","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022;185(20):3652\u201370.","journal-title":"Cell"},{"issue":"9","key":"5998_CR69","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358.","journal-title":"Nat Med"},{"issue":"7","key":"5998_CR70","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41571-023-00767-w","volume":"20","author":"Y Hirata","year":"2023","unstructured":"Hirata Y, et al. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat Rev Clin Oncol. 2023;20(7):453\u201369.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5998_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13073-021-00963-2","volume":"13","author":"Z-H Chen","year":"2021","unstructured":"Chen Z-H, et al. The genomic architecture of EBV and infected gastric tissue from precursor lesions to carcinoma. Genome Medicine. 2021;13(1):146.","journal-title":"Genome Medicine"},{"issue":"6","key":"5998_CR72","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s13402-022-00715-3","volume":"45","author":"E Patrad","year":"2022","unstructured":"Patrad E, et al. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy. Cell Oncol (Dordr). 2022;45(6):1073\u2013117.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"5998_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12935-021-01793-3","volume":"21","author":"Y Luo","year":"2021","unstructured":"Luo Y, et al. Signaling pathways of EBV-induced oncogenesis. Cancer Cell Int. 2021;21(1):93.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"5998_CR74","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2012.01.004","volume":"22","author":"CW Dawson","year":"2012","unstructured":"Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012;22(2):144\u201353.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"5998_CR75","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00589-20","volume":"11","author":"D Nkosi","year":"2020","unstructured":"Nkosi D, et al. Epstein-Barr Virus LMP1 promotes syntenin-1- and Hrs-induced extracellular vesicle formation for its own secretion to increase cell proliferation and migration. MBio. 2020;11(3): e00589-20.","journal-title":"MBio"},{"issue":"2","key":"5998_CR76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2478\/s11658-008-0045-2","volume":"14","author":"M-F Pang","year":"2009","unstructured":"Pang M-F, Lin K-W, Peh S-C. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer. Cell Mol Biol Lett. 2009;14(2):222\u201347.","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"5998_CR77","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3892\/ijo.2014.2252","volume":"44","author":"GB Park","year":"2014","unstructured":"Park GB, et al. ROS-mediated JNK\/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells. Int J Oncol. 2014;44(3):977\u201385.","journal-title":"Int J Oncol"},{"issue":"9","key":"5998_CR78","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/ijc.30816","volume":"141","author":"J Hu","year":"2017","unstructured":"Hu J, et al. The role of oxidative stress in EBV lytic reactivation, radioresistance and the potential preventive and therapeutic implications. Int J Cancer. 2017;141(9):1722\u20139.","journal-title":"Int J Cancer"},{"issue":"21","key":"5998_CR79","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.3390\/cancers13215451","volume":"13","author":"L Wang","year":"2021","unstructured":"Wang L, Ning S. New look of EBV LMP1 signaling landscape. Cancers. 2021;13(21):5451.","journal-title":"Cancers"},{"issue":"3","key":"5998_CR80","first-page":"377","volume":"3","author":"AP Burke","year":"1990","unstructured":"Burke AP, et al. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol. 1990;3(3):377\u201380.","journal-title":"Mod Pathol"},{"key":"5998_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","volume":"495","author":"J Yang","year":"2020","unstructured":"Yang J, et al. Epstein-Barr virus-associated gastric cancer: a distinct subtype. Cancer Lett. 2020;495:191\u20139.","journal-title":"Cancer Lett"},{"issue":"7517","key":"5998_CR82","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research, N","year":"2014","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"1","key":"5998_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112956","volume":"410","author":"J Pandian","year":"2022","unstructured":"Pandian J, Ganesan K. Delineation of gastric tumors with activated ERK\/MAPK signaling cascades for the development of targeted therapeutics. Exp Cell Res. 2022;410(1): 112956.","journal-title":"Exp Cell Res"},{"issue":"9","key":"5998_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00881-23","volume":"97","author":"M Xu","year":"2023","unstructured":"Xu M, et al. Epstein-Barr virus-encoded miR-BART11-3p modulates the DUSP6-MAPK axis to promote gastric cancer cell proliferation and metastasis. J Virol. 2023;97(9): e0088123.","journal-title":"J Virol"},{"issue":"1","key":"5998_CR85","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cell.2009.06.044","volume":"139","author":"Z Paroo","year":"2009","unstructured":"Paroo Z, et al. Phosphorylation of the human microRNA-generating complex mediates MAPK\/Erk signaling. Cell. 2009;139(1):112\u201322.","journal-title":"Cell"},{"issue":"5","key":"5998_CR86","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","volume":"120","author":"SM Johnson","year":"2005","unstructured":"Johnson SM, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635\u201347.","journal-title":"Cell"},{"issue":"4","key":"5998_CR87","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41375-021-01472-2","volume":"36","author":"R Weissman","year":"2022","unstructured":"Weissman R, et al. MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia. 2022;36(4):1139\u201349.","journal-title":"Leukemia"},{"issue":"34","key":"5998_CR88","doi-asserted-by":"publisher","first-page":"26599","DOI":"10.1074\/jbc.M110.115824","volume":"285","author":"J Liu","year":"2010","unstructured":"Liu J, et al. MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras. J Biol Chem. 2010;285(34):26599\u2013607.","journal-title":"J Biol Chem"},{"issue":"14","key":"5998_CR89","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1158\/0008-5472.CAN-09-4531","volume":"70","author":"S Yu","year":"2010","unstructured":"Yu S, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Can Res. 2010;70(14):6015\u201325.","journal-title":"Can Res"},{"issue":"38","key":"5998_CR90","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.2217\/fon-2022-0574","volume":"18","author":"GRL Al-Awsi","year":"2022","unstructured":"Al-Awsi GRL, et al. The role of miRNA-128 in the development and progression of gastrointestinal and urogenital cancer. Future Oncol (London, England). 2022;18(38):4209\u201331.","journal-title":"Future Oncol (London, England)"},{"issue":"3","key":"5998_CR91","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2010.08.013","volume":"18","author":"ME Hatley","year":"2010","unstructured":"Hatley ME, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18(3):282\u201393.","journal-title":"Cancer Cell"},{"issue":"5","key":"5998_CR92","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/carcin\/bgq013","volume":"31","author":"Y Hashimoto","year":"2010","unstructured":"Hashimoto Y, et al. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 2010;31(5):777\u201384.","journal-title":"Carcinogenesis"},{"issue":"10","key":"5998_CR93","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41419-020-03049-w","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun Y, et al. N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN\/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis. 2020;11(10):836.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5998_CR94","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-021-01475-8","volume":"20","author":"D-L Chen","year":"2021","unstructured":"Chen D-L, et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol Cancer. 2021;20(1):166.","journal-title":"Mol Cancer"},{"issue":"5","key":"5998_CR95","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41419-018-0611-0","volume":"9","author":"F Sun","year":"2018","unstructured":"Sun F, et al. miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B. Cell Death Dis. 2018;9(5):522.","journal-title":"Cell Death Dis"},{"key":"5998_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110286","volume":"93","author":"X Li","year":"2022","unstructured":"Li X, et al. MiR-1298-5p level downregulation induced by Helicobacter pylori infection inhibits autophagy and promotes gastric cancer development by targeting MAP2K6. Cell Signal. 2022;93: 110286.","journal-title":"Cell Signal"},{"key":"5998_CR97","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.biopha.2017.10.066","volume":"97","author":"Q-H Qin","year":"2018","unstructured":"Qin Q-H, et al. Long intergenic noncoding RNA 01296 aggravates gastric cancer cells progress through miR-122\/MMP-9. Biomed Pharmacother Biomed Pharmacother. 2018;97:450\u20137.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"5998_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118538","volume":"334","author":"L Ma","year":"2024","unstructured":"Ma L, et al. Weifuchun suppresses the malignancy of gastric cancer cells by targeting KPNA2 through miR-26a-5p-mediated destabilization and the deactivation of the MAPK signaling pathway. J Ethnopharmacol. 2024;334: 118538.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"5998_CR99","doi-asserted-by":"publisher","first-page":"20230776","DOI":"10.1515\/med-2023-0776","volume":"18","author":"J-B Xie","year":"2023","unstructured":"Xie J-B, et al. MiR-1278 targets CALD1 and suppresses the progression of gastric cancer via the MAPK pathway. Open Med (Warsaw, Poland). 2023;18(1):20230776.","journal-title":"Open Med (Warsaw, Poland)"},{"issue":"1","key":"5998_CR100","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12943-022-01702-w","volume":"21","author":"J-X Zhang","year":"2022","unstructured":"Zhang J-X, et al. Retraction Note: Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf\/MEK\/ERK pathway. Mol Cancer. 2022;21(1):227.","journal-title":"Mol Cancer"},{"issue":"14","key":"5998_CR101","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1038\/s41388-020-01610-7","volume":"40","author":"R-R Ma","year":"2021","unstructured":"Ma R-R, et al. MiR-19a\/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer. Oncogene. 2021;40(14):2524\u201338.","journal-title":"Oncogene"},{"key":"5998_CR102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2016.12.033","volume":"389","author":"Y Mi","year":"2017","unstructured":"Mi Y, et al. miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. Cancer Lett. 2017;389:11\u201322.","journal-title":"Cancer Lett"},{"issue":"3","key":"5998_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.5","volume":"8","author":"L Xu","year":"2017","unstructured":"Xu L, et al. Nuclear Drosha enhances cell invasion via an EGFR-ERK1\/2-MMP7 signaling pathway induced by dysregulated miRNA-622\/197 and their targets LAMC2 and CD82 in gastric cancer. Cell Death Dis. 2017;8(3): e2642.","journal-title":"Cell Death Dis"},{"issue":"9","key":"5998_CR104","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1002\/cam4.818","volume":"5","author":"F-Y Liu","year":"2016","unstructured":"Liu F-Y, et al. miR-302b regulates cell cycles by targeting CDK2 via ERK signaling pathway in gastric cancer. Cancer Med. 2016;5(9):2302\u201313.","journal-title":"Cancer Med"},{"issue":"1","key":"5998_CR105","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12885-017-3949-2","volume":"18","author":"B Zeng","year":"2018","unstructured":"Zeng B, Shi W, Tan G. MiR-199a\/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4\/MEK\/ERK signaling pathway. BMC Cancer. 2018;18(1):34.","journal-title":"BMC Cancer"},{"issue":"12","key":"5998_CR106","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","volume":"82","author":"AB Herman","year":"2022","unstructured":"Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82(12):2252\u201366.","journal-title":"Mol Cell"},{"issue":"2","key":"5998_CR107","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202009045","volume":"220","author":"MC Bridges","year":"2021","unstructured":"Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2): e202009045.","journal-title":"J Cell Biol"},{"issue":"1","key":"5998_CR108","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12943-017-0727-3","volume":"16","author":"W-X Peng","year":"2017","unstructured":"Peng W-X, et al. Linc-RoR promotes MAPK\/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer. 2017;16(1):161.","journal-title":"Mol Cancer"},{"issue":"1","key":"5998_CR109","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13046-022-02588-8","volume":"42","author":"T Wu","year":"2023","unstructured":"Wu T, et al. LncRNA BCAR4 promotes migration, invasion, and chemo-resistance by inhibiting miR-644a in breast cancer. J Exp Clin Cancer Res CR. 2023;42(1):14.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"5998_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689992","volume":"9","author":"BM Hussen","year":"2021","unstructured":"Hussen BM, et al. Role of lncRNA BANCR in human cancers: an updated review. Front Cell Dev Biol. 2021;9: 689992.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"5998_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100893","volume":"9","author":"R Li","year":"2014","unstructured":"Li R, et al. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS ONE. 2014;9(6): e100893.","journal-title":"PLoS ONE"},{"key":"5998_CR112","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1476-4598-13-68","volume":"13","author":"M Sun","year":"2014","unstructured":"Sun M, et al. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer. 2014;13:68.","journal-title":"Mol Cancer"},{"issue":"1","key":"5998_CR113","doi-asserted-by":"publisher","first-page":"213","DOI":"10.7150\/thno.16044","volume":"7","author":"K Zhang","year":"2017","unstructured":"Zhang K, et al. Genome-wide lncRNA microarray profiling identifies novel circulating lncRNAs for detection of gastric cancer. Theranostics. 2017;7(1):213\u201327.","journal-title":"Theranostics"},{"key":"5998_CR114","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.omtn.2018.05.009","volume":"12","author":"C Barbagallo","year":"2018","unstructured":"Barbagallo C, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions. Mol Ther Nucleic Acids. 2018;12:229\u201341.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"5998_CR115","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13046-023-02827-6","volume":"42","author":"C Zhang","year":"2023","unstructured":"Zhang C, et al. LncRNA CCAT1 facilitates the progression of gastric cancer via PTBP1-mediated glycolysis enhancement. J Exp Clin Cancer Res CR. 2023;42(1):246.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"3","key":"5998_CR116","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/cpr.12252","volume":"49","author":"Y Xin","year":"2016","unstructured":"Xin Y, et al. CCAT1: a pivotal oncogenic long non-coding RNA in human cancers. Cell Prolif. 2016;49(3):255\u201360.","journal-title":"Cell Prolif"},{"issue":"1","key":"5998_CR117","doi-asserted-by":"publisher","first-page":"15369","DOI":"10.1038\/s41598-021-94576-9","volume":"11","author":"T Olesi\u0144ski","year":"2021","unstructured":"Olesi\u0144ski T, et al. Long noncoding RNA CCAT1 rs67085638 SNP contribution to the progression of gastric cancer in a Polish population. Sci Rep. 2021;11(1):15369.","journal-title":"Sci Rep"},{"issue":"1","key":"5998_CR118","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12864-022-08578-6","volume":"23","author":"H Razavi","year":"2022","unstructured":"Razavi H, Katanforosh A. Identification of novel key regulatory lncRNAs in gastric adenocarcinoma. BMC Genomics. 2022;23(1):352.","journal-title":"BMC Genomics"},{"issue":"6","key":"5998_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.205","volume":"8","author":"T-P Xu","year":"2017","unstructured":"Xu T-P, et al. E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR\/STAU1\/CDKN2B signaling axis. Cell Death Dis. 2017;8(6): e2837.","journal-title":"Cell Death Dis"},{"issue":"5","key":"5998_CR120","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/carcin\/bgac018","volume":"43","author":"Z Gao","year":"2022","unstructured":"Gao Z, et al. LncRNA LINC02253 activates KRT18\/MAPK\/ERK pathway by mediating N6-methyladenosine modification of KRT18 mRNA in gastric cancer. Carcinogenesis. 2022;43(5):419\u201329.","journal-title":"Carcinogenesis"},{"key":"5998_CR121","doi-asserted-by":"publisher","first-page":"112235","DOI":"10.1016\/j.biopha.2021.112235","volume":"143","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Zhong C, Duan S. The tumorigenic function of LINC00858 in cancer. Biomed Pharmacother Biomed Pharmacother. 2021;143:112235.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"issue":"7","key":"5998_CR122","first-page":"3657","volume":"24","author":"GR Zhou","year":"2020","unstructured":"Zhou GR, et al. Long non-coding RNA BCAR4 accelerates cell proliferation and suppresses cell apoptosis in gastric cancer via regulating MAPK\/ERK signaling. Eur Rev Med Pharmacol Sci. 2020;24(7):3657\u201364.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5998_CR123","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2147\/OTT.S217452","volume":"13","author":"Y Shi","year":"2020","unstructured":"Shi Y, Sun H. Down-regulation of lncRNA LINC00152 suppresses gastric cancer cell migration and invasion through inhibition of the ERK\/MAPK signaling pathway. Onco Targets Ther. 2020;13:2115\u201324.","journal-title":"Onco Targets Ther"},{"issue":"20","key":"5998_CR124","first-page":"8852","volume":"23","author":"CX Qu","year":"2019","unstructured":"Qu CX, et al. LncRNA AOC4P affects biological behavior of gastric cancer cells through MAPK signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(20):8852\u201360.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"5998_CR125","first-page":"588","volume":"23","author":"JF Li","year":"2019","unstructured":"Li JF, et al. Long non-coding RNA PICART1 inhibits cell proliferation by regulating the PI3K\/AKT and MAPK\/ERK signaling pathways in gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(2):588\u201397.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5998_CR126","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.lfs.2018.07.032","volume":"208","author":"Y Li","year":"2018","unstructured":"Li Y, et al. Long noncoding RNA SNHG6 regulates p21 expression via activation of the JNK pathway and regulation of EZH2 in gastric cancer cells. Life Sci. 2018;208:295\u2013304.","journal-title":"Life Sci"},{"issue":"8","key":"5998_CR127","first-page":"3522","volume":"8","author":"P Li","year":"2016","unstructured":"Li P, et al. Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway. Am J Transl Res. 2016;8(8):3522\u20139.","journal-title":"Am J Transl Res"},{"key":"5998_CR128","doi-asserted-by":"publisher","first-page":"8589","DOI":"10.2147\/CMAR.S186002","volume":"11","author":"H Zhang","year":"2019","unstructured":"Zhang H, Zhang Z, Wang D. Epigenetic regulation of IncRNA KCNKI5-ASI in gastric cancer. Cancer Manag Res. 2019;11:8589\u2013602.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"5998_CR129","first-page":"1545","volume":"54","author":"R Fu","year":"2019","unstructured":"Fu R, et al. Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway. Int J Oncol. 2019;54(5):1545\u201354.","journal-title":"Int J Oncol"},{"key":"5998_CR130","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.2147\/OTT.S168819","volume":"11","author":"L Wu","year":"2018","unstructured":"Wu L, et al. A long noncoding RNA MAP3K1-2 promotes proliferation and invasion in gastric cancer. Onco Targets Ther. 2018;11:4631\u20139.","journal-title":"Onco Targets Ther"},{"issue":"8","key":"5998_CR131","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1111\/jcmm.13661","volume":"22","author":"D Li","year":"2018","unstructured":"Li D, et al. Linc00483 as ceRNA regulates proliferation and apoptosis through activating MAPKs in gastric cancer. J Cell Mol Med. 2018;22(8):3875\u201386.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"5998_CR132","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1158\/1078-0432.CCR-18-2804","volume":"25","author":"X Wang","year":"2019","unstructured":"Wang X, et al. C8orf76 promotes gastric tumorigenicity and metastasis by directly inducing lncRNA DUSP5P1 and associates with patient outcomes. Clin Cancer Res. 2019;25(10):3128\u201340.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5998_CR133","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3892\/mmr.2016.5361","volume":"14","author":"H-L Li","year":"2016","unstructured":"Li H-L, et al. MAPK pathways are involved in the inhibitory effect of berberine hydrochloride on gastric cancer MGC 803 cell proliferation and IL-8 secretion in vitro and in vivo. Mol Med Rep. 2016;14(2):1430\u20138.","journal-title":"Mol Med Rep"},{"key":"5998_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110245","volume":"128","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, et al. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK\/mTOR\/p70S6K and Akt signaling pathways. Biomed Pharmacother Biomed Pharmacother. 2020;128: 110245.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"issue":"2","key":"5998_CR135","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ptr.7652","volume":"37","author":"L Ouyang","year":"2023","unstructured":"Ouyang L, et al. Chinese dragon\u2019s blood ethyl acetate extract suppresses gastric cancer progression through induction of apoptosis and autophagy mediated by activation of MAPK and downregulation of the mTOR-Beclin1 signalling cascade. Phytother Res PTR. 2023;37(2):689\u2013701.","journal-title":"Phytother Res PTR"},{"key":"5998_CR136","first-page":"58","volume":"51","author":"Z Xu","year":"2018","unstructured":"Xu Z, et al. Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA. Phytomed Int J Phytother Phytopharmacol. 2018;51:58\u201367.","journal-title":"Phytomed Int J Phytother Phytopharmacol"},{"key":"5998_CR137","doi-asserted-by":"publisher","first-page":"1282203","DOI":"10.3389\/fphar.2023.1282203","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang P, Liu W, Wang Y. The mechanisms of tanshinone in the treatment of tumors. Front Pharmacol. 2023;14:1282203.","journal-title":"Front Pharmacol"},{"key":"5998_CR138","doi-asserted-by":"publisher","first-page":"111876","DOI":"10.1016\/j.biopha.2021.111876","volume":"141","author":"J Zhang","year":"2021","unstructured":"Zhang J, et al. Cudraxanthone L inhibits gastric cancer by regulating the MAPK signalling and promoting FAS-mediated pathway. Biomed Pharmacother Biomed Pharmacother. 2021;141:111876.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"issue":"1","key":"5998_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1631\/jzus.B2100182","volume":"23","author":"Y Lu","year":"2022","unstructured":"Lu Y, et al. A comprehensive update: gastrointestinal microflora, gastric cancer and gastric premalignant condition, and intervention by traditional Chinese medicine. J Zhejiang Univ Sci B. 2022;23(1):1\u201318.","journal-title":"J Zhejiang Univ Sci B"},{"key":"5998_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.117988","volume":"326","author":"L Yu","year":"2024","unstructured":"Yu L, et al. Xianglian Pill combined with 5-fluorouracil enhances antitumor activity and reduces gastrointestinal toxicity in gastric cancer by regulating the p38 MAPK\/NF-\u03baB signaling pathway. J Ethnopharmacol. 2024;326: 117988.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"5998_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.13","volume":"7","author":"C Deng","year":"2016","unstructured":"Deng C, et al. Low nanomolar concentrations of Cucurbitacin-I induces G2\/M phase arrest and apoptosis by perturbing redox homeostasis in gastric cancer cells in vitro and in vivo. Cell Death Dis. 2016;7(2): e2106.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5998_CR142","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/jcb.27542","volume":"120","author":"J Mu","year":"2019","unstructured":"Mu J, et al. Curcumin derivative L6H4 inhibits proliferation and invasion of gastric cancer cell line BGC-823. J Cell Biochem. 2019;120(1):1011\u20137.","journal-title":"J Cell Biochem"},{"issue":"7","key":"5998_CR143","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/nu16070965","volume":"16","author":"N-R Choi","year":"2024","unstructured":"Choi N-R, et al. Exploring the therapeutic effects of Atractylodes macrocephala Koidz against human gastric cancer. Nutrients. 2024;16(7):965.","journal-title":"Nutrients"},{"key":"5998_CR144","doi-asserted-by":"publisher","first-page":"153473542095321","DOI":"10.1177\/1534735420953215","volume":"19","author":"Z Gu","year":"2020","unstructured":"Gu Z, et al. A review of therapeutic effects and the pharmacological molecular mechanisms of Chinese Medicine Weifuchun in treating precancerous gastric conditions. Integr Cancer Ther. 2020;19:1534735420953215.","journal-title":"Integr Cancer Ther"},{"key":"5998_CR145","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.biopha.2016.03.046","volume":"81","author":"J Shen","year":"2016","unstructured":"Shen J, et al. Lobetyol activate MAPK pathways associated with G1\/S cell cycle arrest and apoptosis in MKN45 cells in vitro and in vivo. Biomed Pharmacother Biomed Pharmacother. 2016;81:120\u20137.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"issue":"2","key":"5998_CR146","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1142\/S0192415X21500245","volume":"49","author":"D Qiao","year":"2021","unstructured":"Qiao D, et al. Baicalein inhibits gastric cancer cell proliferation and migration through a FAK interaction via AKT\/mTOR signaling. Am J Chin Med. 2021;49(2):525\u201341.","journal-title":"Am J Chin Med"},{"issue":"21","key":"5998_CR147","doi-asserted-by":"publisher","first-page":"8307","DOI":"10.3390\/ijms21218307","volume":"21","author":"S Nakonieczna","year":"2020","unstructured":"Nakonieczna S, Grabarska A, Kukula-Koch W. The potential anticancer activity of phytoconstituents against gastric cancer-a review on in vitro, in vivo, and clinical studies. Int J Mol Sci. 2020;21(21):8307.","journal-title":"Int J Mol Sci"},{"key":"5998_CR148","volume":"123","author":"Y-Q Deng","year":"2024","unstructured":"Deng Y-Q, et al. Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities. Phytomed Int J Phytother Phytopharmacol. 2024;123: 155169.","journal-title":"Phytomed Int J Phytother Phytopharmacol"},{"issue":"9","key":"5998_CR149","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/hh2101.099504","volume":"89","author":"JL Martin","year":"2001","unstructured":"Martin JL, et al. Antiischemic effects of SB203580 are mediated through the inhibition of p38alpha mitogen-activated protein kinase: evidence from ectopic expression of an inhibition-resistant kinase. Circ Res. 2001;89(9):750\u20132.","journal-title":"Circ Res"},{"issue":"1","key":"5998_CR150","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.bjp.0703534","volume":"131","author":"KU Birkenkamp","year":"2000","unstructured":"Birkenkamp KU, et al. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol. 2000;131(1):99\u2013107.","journal-title":"Br J Pharmacol"},{"key":"5998_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113006","volume":"211","author":"C Korzeniecki","year":"2021","unstructured":"Korzeniecki C, Priefer R. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway. Eur J Med Chem. 2021;211: 113006.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"5998_CR152","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/13543776.2020.1749263","volume":"30","author":"V Haller","year":"2020","unstructured":"Haller V, et al. An updated patent review of p38 MAP kinase inhibitors (2014\u20132019). Expert Opin Ther Pat. 2020;30(6):453\u201366.","journal-title":"Expert Opin Ther Pat"},{"issue":"7","key":"5998_CR153","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/ijms21072531","volume":"21","author":"MH Shin","year":"2020","unstructured":"Shin MH, et al. Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade. Int J Mol Sci. 2020;21(7):2531.","journal-title":"Int J Mol Sci"},{"key":"5998_CR154","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/352371","volume":"2014","author":"Y Yang","year":"2014","unstructured":"Yang Y, et al. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediat Inflamm. 2014;2014: 352371.","journal-title":"Mediat Inflamm"},{"key":"5998_CR155","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biochem-081720-114505","volume":"91","author":"N Ronkina","year":"2022","unstructured":"Ronkina N, Gaestel M. MAPK-activated protein kinases: servant or partner? Annu Rev Biochem. 2022;91:505\u201340.","journal-title":"Annu Rev Biochem"},{"key":"5998_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113473","volume":"220","author":"X Liang","year":"2021","unstructured":"Liang X, et al. An update of new small-molecule anticancer drugs approved from 2015 to 2020. Eur J Med Chem. 2021;220: 113473.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"5998_CR157","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","volume":"11","author":"Z Song","year":"2021","unstructured":"Song Z, et al. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharmaceutica Sinica B. 2021;11(1):13\u201329.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"5","key":"5998_CR158","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.apsb.2021.12.022","volume":"12","author":"X Pan","year":"2022","unstructured":"Pan X, et al. Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy. Acta Pharmaceutica Sinica B. 2022;12(5):2171\u201392.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"20","key":"5998_CR159","doi-asserted-by":"publisher","first-page":"13561","DOI":"10.1021\/acs.jmedchem.2c01244","volume":"65","author":"L Fu","year":"2022","unstructured":"Fu L, et al. Targeting extracellular signal-regulated protein kinase 1\/2 (ERK1\/2) in cancer: an update on pharmacological small-molecule inhibitors. J Med Chem. 2022;65(20):13561\u201373.","journal-title":"J Med Chem"},{"issue":"2","key":"5998_CR160","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/1061186X.2019.1648477","volume":"28","author":"L Miao","year":"2020","unstructured":"Miao L, Tian H. Development of ERK1\/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations. J Drug Target. 2020;28(2):154\u201365.","journal-title":"J Drug Target"},{"issue":"2","key":"5998_CR161","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s43440-021-00238-y","volume":"73","author":"KS Abdelrahman","year":"2021","unstructured":"Abdelrahman KS, et al. JNK signaling as a target for anticancer therapy. Pharmacol Rep PR. 2021;73(2):405\u201334.","journal-title":"Pharmacol Rep PR"},{"issue":"3","key":"5998_CR162","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3390\/ijms25031848","volume":"25","author":"D-T Morgos","year":"2024","unstructured":"Morgos D-T, et al. Targeting PI3K\/AKT\/mTOR and MAPK signaling pathways in gastric cancer. Int J Mol Sci. 2024;25(3):1848.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"5998_CR163","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.3390\/cancers13143540","volume":"13","author":"H Maadi","year":"2021","unstructured":"Maadi H, et al. Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers. 2021;13(14):3540.","journal-title":"Cancers"},{"issue":"1","key":"5998_CR164","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"D-Y Oh","year":"2020","unstructured":"Oh D-Y, Bang Y-J. HER2-targeted therapies\u2014a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"5998_CR165","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-13-1549","volume":"20","author":"K Gala","year":"2014","unstructured":"Gala K, Chandarlapaty S. Molecular pathways: HER3 targeted therapy. Clin Cancer Res. 2014;20(6):1410\u20136.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5998_CR166","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.6004\/jnccn.2016.0138","volume":"14","author":"K Shitara","year":"2016","unstructured":"Shitara K, Ohtsu A. Advances in systemic therapy for metastatic or advanced gastric cancer. J Natl Compr Cancer Netw JNCCN. 2016;14(10):1313\u201320.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"Suppl 3","key":"5998_CR167","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0305-7372(10)70014-1","volume":"36","author":"F De Vita","year":"2010","unstructured":"De Vita F, et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev. 2010;36(Suppl 3):S11\u20135.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"5998_CR168","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.critrevonc.2012.08.008","volume":"85","author":"RA Pazo Cid","year":"2013","unstructured":"Pazo Cid RA, Ant\u00f3n A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol. 2013;85(3):350\u201362.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"5998_CR169","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11864-021-00884-7","volume":"22","author":"BC Grieb","year":"2021","unstructured":"Grieb BC, Agarwal R. HER2-directed therapy in advanced gastric and gastroesophageal adenocarcinoma: triumphs and troubles. Curr Treat Options Oncol. 2021;22(10):88.","journal-title":"Curr Treat Options Oncol"},{"issue":"127","key":"5998_CR170","doi-asserted-by":"publisher","first-page":"12rv72","DOI":"10.1126\/scitranslmed.3001539","volume":"4","author":"HM Stern","year":"2012","unstructured":"Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med. 2012;4(127):12rv72.","journal-title":"Sci Transl Med"},{"issue":"10","key":"5998_CR171","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.3390\/jcm12103391","volume":"12","author":"S Ariga","year":"2023","unstructured":"Ariga S. History and future of HER2-targeted therapy for advanced gastric cancer. J Clin Med. 2023;12(10):3991.","journal-title":"J Clin Med"},{"issue":"1","key":"5998_CR172","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-023-01406-7","volume":"8","author":"L-Y Zhao","year":"2023","unstructured":"Zhao L-Y, et al. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduct Target Ther. 2023;8(1):201.","journal-title":"Signal Transduct Target Ther"},{"issue":"20","key":"5998_CR173","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1016\/j.cell.2022.09.015","volume":"185","author":"AB Dohlman","year":"2022","unstructured":"Dohlman AB, et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022;185(20):3807\u201322.","journal-title":"Cell"},{"issue":"1","key":"5998_CR174","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gpb.2017.06.002","volume":"16","author":"C Meng","year":"2018","unstructured":"Meng C, et al. Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bioinform. 2018;16(1):33\u201349.","journal-title":"Genomics Proteomics Bioinform"},{"issue":"12","key":"5998_CR175","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41419-021-04396-y","volume":"12","author":"D Dai","year":"2021","unstructured":"Dai D, et al. Interactions between gastric microbiota and metabolites in gastric cancer. Cell Death Dis. 2021;12(12):1104.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5998_CR176","doi-asserted-by":"publisher","first-page":"1909459","DOI":"10.1080\/19490976.2021.1909459","volume":"13","author":"C-C Chen","year":"2021","unstructured":"Chen C-C, et al. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1909459.","journal-title":"Gut Microbes"},{"issue":"9","key":"5998_CR177","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1136\/gutjnl-2019-319696","volume":"69","author":"Y Guo","year":"2020","unstructured":"Guo Y, et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69(9):1598\u2013607.","journal-title":"Gut"},{"key":"5998_CR178","doi-asserted-by":"publisher","first-page":"1183331","DOI":"10.3389\/fimmu.2023.1183331","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang M, et al. The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy. Front Immunol. 2023;14:1183331.","journal-title":"Front Immunol"},{"issue":"1","key":"5998_CR179","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/21655979.2021.1889109","volume":"12","author":"Y Fang","year":"2021","unstructured":"Fang Y, et al. The roles of microbial products in the development of colorectal cancer: a review. Bioengineered. 2021;12(1):720\u201335.","journal-title":"Bioengineered"},{"issue":"1","key":"5998_CR180","doi-asserted-by":"publisher","first-page":"2089003","DOI":"10.1080\/19490976.2022.2089003","volume":"14","author":"K Arnauts","year":"2022","unstructured":"Arnauts K, et al. Microbiota, not host origin drives ex vivo intestinal epithelial responses. Gut Microbes. 2022;14(1):2089003.","journal-title":"Gut Microbes"},{"key":"5998_CR181","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.freeradbiomed.2016.10.495","volume":"105","author":"RM Jones","year":"2017","unstructured":"Jones RM, Neish AS. Redox signaling mediated by the gut microbiota. Free Radical Biol Med. 2017;105:41\u20137.","journal-title":"Free Radical Biol Med"},{"issue":"19","key":"5998_CR182","doi-asserted-by":"publisher","first-page":"11990","DOI":"10.3390\/ijms231911990","volume":"23","author":"M Guardamagna","year":"2022","unstructured":"Guardamagna M, et al. Gut microbiota and therapy in metastatic melanoma: focus on MAPK pathway inhibition. Int J Mol Sci. 2022;23(19):11990.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05998-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05998-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05998-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T22:02:58Z","timestamp":1735077778000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05998-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5998"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05998-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors report no relevant conflicts of interest for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1142"}}